🔷 Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision
This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives NCCN risk stratification and active-surveillance/surgery/radiotherapy + ADT/chemotherapy principles.
Clinical takeaway
Metastatic first-line therapy combines ADT early with an ARPI or docetaxel rather than using ADT alone. (original synthesis · not guideline verbatim)
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to decide biopsy versus follow-up (1–2 mostly follow-up, 3 by PSAD, 4–5 biopsy) and, once ISUP/stage are known, to stratify risk and outline treatment.
How it works
PI-RADS + PSAD (threshold 0.15) → biopsy decision. ISUP grade + PSA band + cT → NCCN risk group (low/favorable-int/unfavorable-int/high/very-high) → surveillance vs RP vs EBRT + ADT, with chemotherapy/ARPI for advanced disease.
Key points
- Metastatic first-line therapy combines ADT early with an ARPI or docetaxel rather than using ADT alone. (original synthesis · not guideline verbatim)
- PSAD < 0.15 with a negative DRE supports deferring biopsy at PI-RADS 1–3.
- Diagnosis relies on biopsy pathology, and the simplified risk stratification must integrate core involvement, PSAD, and genomics.
References
- Turkbey B, et al. Prostate Imaging Reporting and Data System Version 2.1 (PI-RADS v2.1). Eur Urol 2019.
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Prostate Cancer.
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| PI-RADS v2.1 category (mpMRI) | 1 |
|---|---|
| Serum PSA | 6.5 ng/mL |
| Prostate volume (for PSAD) | 50 mL |
| Digital rectal exam DRE | No nodule palpated |
| ISUP/grade group (if biopsied) | Not biopsied/unknown |
| Clinical stage cT (if diagnosed) | Unknown |
→ConclusionPI-RADS 1 · follow-up
- (1) Assessment & biopsy decision：PI-RADS 1: low probability of clinically significant cancer (csPCa). (PSAD ≈ 0.130 ng/mL/cc) PSAD < 0.15 and DRE negative → may defer biopsy, follow with PSA/MRI.
- Note：If biopsy-confirmed, entering ISUP grade, PSA, and clinical stage can continue to give risk stratification, surgery, and radiotherapy/chemotherapy principles.
- Basis：PI-RADS v2.1 (ACR/ESUR 2019) + PSAD 0.15 consensus; NCCN prostate cancer v2.2025; EAU guideline; CSCO prostate cancer guideline.
| PI-RADS v2.1 category (mpMRI) | 5 |
|---|---|
| Serum PSA | 6.5 ng/mL |
| Prostate volume (for PSAD) | 50 mL |
| Digital rectal exam DRE | Suspicious nodule palpated |
| ISUP/grade group (if biopsied) | 5 (Gleason 9–10) |
| Clinical stage cT (if diagnosed) | T3b–T4 |
→ConclusionPI-RADS 5 · diagnosed treatment decision
- (1) Assessment & biopsy decision：PI-RADS 5: biopsy strongly recommended (targeted + systematic). (PSAD ≈ 0.130 ng/mL/cc)
- (2) Risk stratification：ISUP grade 5 / PSA < 10 / clinical stage t3b_t4 → NCCN very high risk.
- (3) Management strategy & surgery：Multimodal: EBRT + long-course ADT (± abiraterone), or RP + extended PLND + adjuvant therapy. Needs full staging (PSMA-PET/bone scan) to exclude metastasis. Surgical procedure: radical prostatectomy (robotic/laparoscopic preferred), with PLND extent and nerve-sparing decided by risk.
Frequently asked questions
- What is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
- This tool combines PI-RADS, PSA density, and DRE for biopsy/follow-up triage, then after diagnosis gives NCCN risk stratification and active-surveillance/surgery/radiotherapy + ADT/chemotherapy principles.
- How is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision calculated? What is the core formula?
- PI-RADS + PSAD (threshold 0.15) → biopsy decision. ISUP grade + PSA band + cT → NCCN risk group (low/favorable-int/unfavorable-int/high/very-high) → surveillance vs RP vs EBRT + ADT, with chemotherapy/ARPI for advanced disease.
- When is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision used?
- Use to decide biopsy versus follow-up (1–2 mostly follow-up, 3 by PSAD, 4–5 biopsy) and, once ISUP/stage are known, to stratify risk and outline treatment.
- What are the key clinical points for Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
- Metastatic first-line therapy combines ADT early with an ARPI or docetaxel rather than using ADT alone. (original synthesis · not guideline verbatim) PSAD < 0.15 with a negative DRE supports deferring biopsy at PI-RADS 1–3. Diagnosis relies on biopsy pathology, and the simplified risk stratification must integrate core involvement, PSAD, and genomics.
- What are the limits and cautions when using Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Prostate Nodule Smart Manager · Assessment, Follow-up & Treatment Decision calculated in practice? Can you show a worked example?
- Inputs: PI-RADS v2.1 category (mpMRI) 1, Serum PSA 6.5 ng/mL, Prostate volume (for PSAD) 50 mL, Digital rectal exam DRE No nodule palpated, ISUP/grade group (if biopsied) Not biopsied/unknown, Clinical stage cT (if diagnosed) Unknown → Result: Conclusion PI-RADS 1 · follow-up（(1) Assessment & biopsy decision: PI-RADS 1: low probability of clinically significant cancer (csPCa). (PSAD ≈ 0.130 ng/mL/cc) PSAD < 0.15 and DRE negative → may defer biopsy, follow with PSA/MRI., Note: If biopsy-confirmed, entering ISUP grade, PSA, and clinical stage can continue to give risk stratification, surgery, and radiotherapy/chemotherapy principles., Basis: PI-RADS v2.1 (ACR/ESUR 2019) + PSAD 0.15 consensus; NCCN prostate cancer v2.2025; EAU guideline; CSCO prostate cancer guideline.） Inputs: PI-RADS v2.1 category (mpMRI) 5, Serum PSA 6.5 ng/mL, Prostate volume (for PSAD) 50 mL, Digital rectal exam DRE Suspicious nodule palpated, ISUP/grade group (if biopsied) 5 (Gleason 9–10), Clinical stage cT (if diagnosed) T3b–T4 → Result: Conclusion PI-RADS 5 · diagnosed treatment decision（(1) Assessment & biopsy decision: PI-RADS 5: biopsy strongly recommended (targeted + systematic). (PSAD ≈ 0.130 ng/mL/cc), (2) Risk stratification: ISUP grade 5 / PSA < 10 / clinical stage t3b_t4 → NCCN very high risk., (3) Management strategy & surgery: Multimodal: EBRT + long-course ADT (± abiraterone), or RP + extended PLND + adjuvant therapy. Needs full staging (PSMA-PET/bone scan) to exclude metastasis. Surgical procedure: radical prostatectomy (robotic/laparoscopic preferred), with PLND extent and nerve-sparing decided by risk.）